Developer docs
API playgroundTry for free, no card

Search company profiles

Nordmark Pharma

Full company profile

uuid000impq

Namestring
Nordmark Pharma
Legal namestring
Nordmark Pharma GmbH
Company typeenum
Private
Founded yearint
1930
Descriptiontext

Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer headquartered in Uetersen, Schleswig-Holstein, with additional process development operations at BIBITEC in Bielefeld. The company specializes in the manufacture of active pharmaceutical ingredients (APIs) and finished drug products of biological and biotechnological origin, and self-describes as worldwide leading in the production of pancreatin and collagenase. Its portfolio spans three integrated business lines: (1) proprietary pharmaceutical products including Pankreatan for pancreatic exocrine insufficiency and Thrombophob 60.000 (heparin-based topical), distributed via pharmacies; (2) a biochemicals portfolio under the Collagenase NB and Neutral Protease NB brands sold globally for in vitro research and clinical cell-isolation use; and (3) a full-service CDMO offering covering microbial fermentation (up to 500 L pilot scale), mammalian cell culture (up to 200 L via BIBITEC), downstream processing, and drug product formulation (orals, topicals, parenterals) under cGMP for Phase I-III clinical and commercial supply.

The company operates at FDA-audited, highest cGMP quality levels and serves four primary customer segments: biopharmaceutical companies seeking CDMO partnerships, healthcare professionals prescribing Pankreatan/Thrombophob, research institutions and clinics purchasing biochemicals, and patients receiving branded products through pharmacies. Its go-to-market combines direct enterprise sales, participation in major industry congresses (EPC, DPC, BIO, CPhI, German Biotech Days), the GastroLive digital training series for gastroenterologists, and dedicated HCP/pharmacy service portals. Ownership is independent and private, led by CEO Dr. Jörn Tonne and four additional managing directors, with Ulf Tonne chairing the supervisory board; the firm employs 501-1000 people and has no disclosed external funding rounds or parent company.

Short descriptiontext

Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer specializing in biological and biotechnological APIs (world leader in pancreatin and collagenase), branded products (Pankreatan, Thrombophob), and full-service CDMO services for global biopharma, research, and healthcare customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersUetersen, Germany
HQ citystring
Uetersen
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical manufacturing, contract development manufacturing, active pharmaceutical ingredients, pancreatin collagenase production, biological drug substance
Industry2 codes
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Medicinal Chemicals & Botanical Products2833
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Products
TypeOne Time License
Description

Sale of finished pharmaceutical products including Pankreatan (pancreatin) for pancreatic enzyme replacement therapy and Thrombophob (heparin-based cream) for sports injuries and superficial phlebitis. Products sold to patients via pharmacies and to healthcare professionals.

nordmark-pharma.de
2Biochemicals
TypeOne Time License
Description

Sale of biochemical products including collagenases, neutral proteases, and clostripain for research and clinical applications. These are sold for in vitro use only, for research and laboratory purposes.

nordmark-pharma.de
3Contract Manufacturing Services
TypeProfessional Services
Description

Full service CDMO offering for biopharmaceutical companies - from development, analytical testing, clinical trials, regulatory support, and project management through to GMP manufacturing of drug substances and drug products for clinical supply (Phase I-III).

nordmark-pharma.de
4Thyroid Extract
TypeOne Time License
Description

Production and sale of desiccated thyroid extract as a pharmaceutical product.

nordmark-pharma.de
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Pankreatan
Description

Pharmaceutical product for pancreatic exocrine insufficiency (PEI)

nordmark-pharma.de
+4 more records
Core offering1 text field

Nordmark Pharma is a biopharmaceutical Full Service Provider specializing in the manufacture of active pharmaceutical ingredients and drug products of biological and biotechnological origin. The company offers the complete pharmaceutical value chain as a one-stop-shop—from development, analytical testing, clinical trial supply, regulatory support, and project management through to GMP manufacturing of drug substances and finished drug products. It also sells proprietary finished medications (Pankreatan, Thrombophob) and a comprehensive biochemical enzyme portfolio (Collagenase NB, Neutral Protease, Clostripain) for research and clinical applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Nordmark Pharma operates as a biopharmaceutical Full Service Provider offering a vertically integrated portfolio combining proprietary pharmaceutical products and contract development and manufacturing (CDMO) services. The pharmaceutical arm includes patient medications Pankreatan (pancreatic enzyme replacement for exocrine insufficiency) and Thrombophob 60.000 (heparin-based topical for injuries and phlebitis), alongside active pharmaceutical ingredients Pancreatin, Collagenase, and Desiccated Thyroid Extract where Nordmark holds global market leadership positions. The biochemicals portfolio features the comprehensive Collagenase NB product line in multiple grades (Premium, Proved, Standard, Sterile, GMP, Gentle, Broad Range) plus Neutral Protease and Clostripain enzymes for research and clinical applications. Through subsidiaries Nordmark Biotech and BIBITEC, the company provides end-to-end CDMO services spanning drug substance manufacturing via microbial fermentation (up to 500L) and mammalian cell culture (up to 200L), through drug product formulation (orals, topicals, parenterals), all under cGMP conditions for clinical trial supply (Phase I-III) and commercial production—positioniting Nordmark as a one-stop-shop covering the complete pharmaceutical value chain from development through regulatory approval and market supply.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BIBITEC is a wholly-owned subsidiary of Nordmark conducting mammalian cell culture-based process development and protein production. Located in Bielefeld, Germany, BIBITEC handles upstream development of mammalian cell culture processes from lab scale (<1 L) to pilot scale (up to 200 L) for GMP clinical supply manufacturing.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-headquartered CDMO offering mammalian and microbial GMP biomanufacturing plus process development for clinical and commercial supply. Highly comparable technology stack (CHO/microbial) and mid-market European CDMO positioning.

TypeDirect peer
Description

Swiss CDMO offering API manufacturing including biologics and finished drug products to pharma clients. Comparable vertical integration from API to finished dosage form and European-headquartered mid-market CDMO profile.

TypeBroad incumbent
Description

German specialty/generic pharmaceutical company selling finished drug products across Europe. Comparable as a German-headquartered branded specialty pharma selling into pharmacies and HCPs, though at significantly larger scale and broader portfolio than Nordmark.

TypeBroad incumbent
Description

Global biologics CDMO offering cell-line development, process development, and GMP manufacturing for mammalian-based biotherapeutics. Comparable full-service value proposition but at commercial-scale bioreactor capacities.

TypeBroad incumbent
Description

Global leader in mammalian and microbial biologics contract manufacturing across all clinical and commercial scales. Competes with Nordmark for European biopharma CDMO work but at vastly larger capacity (10,000L+ stainless and 2,000L+ single-use).

TypeDirect peer
Description

German-based biologics CDMO with BSL-2 viral and gene therapy capabilities using mammalian and microbial expression systems. Comparable full-service positioning and German regulatory footprint to Nordmark Biotech.

TypeRegional player
Description

German supplier of biochemicals, enzymes, and life-science research reagents serving European academic and biotech customers. Comparable as a German specialty biochemical products supplier, though broader product scope.

TypeDirect peer
Description

German biopharmaceutical CDMO focused on mammalian cell-culture process development and GMP manufacturing for clinical supply. Closely comparable to Nordmark's BIBITEC unit in scale (pilot-to-Phase III mammalian CDMO) and customer profile (European biotechs).

TypeDirect peer
Description

US-based supplier of collagenase, protease, and other enzymes for cell isolation and bioprocessing applications. Directly comparable biochemical product portfolio to Nordmark Biochemicals' Collagenase NB and Neutral Protease lines.

10Boehringer Ingelheim BioXcellence
TypeBroad incumbent
Description

Larger German biopharmaceutical CDMO division of Boehringer Ingelheim offering mammalian and microbial contract manufacturing at commercial scale. Overlaps with Nordmark's CDMO offering but operates at materially larger bioreactor scale.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nordmark Pharma

Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer specializing in biological and biotechnological APIs (world leader in pancreatin and collagenase), branded products (Pankreatan, Thrombophob), and full-service CDMO services for global biopharma, research, and healthcare customers.

What Nordmark Pharma does

Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer headquartered in Uetersen, Schleswig-Holstein, with additional process development operations at BIBITEC in Bielefeld. The company specializes in the manufacture of active pharmaceutical ingredients (APIs) and finished drug products of biological and biotechnological origin, and self-describes as worldwide leading in the production of pancreatin and collagenase. Its portfolio spans three integrated business lines: (1) proprietary pharmaceutical products including Pankreatan for pancreatic exocrine insufficiency and Thrombophob 60.000 (heparin-based topical), distributed via pharmacies; (2) a biochemicals portfolio under the Collagenase NB and Neutral Protease NB brands sold globally for in vitro research and clinical cell-isolation use; and (3) a full-service CDMO offering covering microbial fermentation (up to 500 L pilot scale), mammalian cell culture (up to 200 L via BIBITEC), downstream processing, and drug product formulation (orals, topicals, parenterals) under cGMP for Phase I-III clinical and commercial supply.

The company operates at FDA-audited, highest cGMP quality levels and serves four primary customer segments: biopharmaceutical companies seeking CDMO partnerships, healthcare professionals prescribing Pankreatan/Thrombophob, research institutions and clinics purchasing biochemicals, and patients receiving branded products through pharmacies. Its go-to-market combines direct enterprise sales, participation in major industry congresses (EPC, DPC, BIO, CPhI, German Biotech Days), the GastroLive digital training series for gastroenterologists, and dedicated HCP/pharmacy service portals. Ownership is independent and private, led by CEO Dr. Jörn Tonne and four additional managing directors, with Ulf Tonne chairing the supervisory board; the firm employs 501-1000 people and has no disclosed external funding rounds or parent company.

Nordmark Pharma firmographics

Firmographics
Name
Nordmark Pharma
Legal name
Nordmark Pharma GmbH
Website
https://nordmark-pharma.de
Company type
Private
Founded year
1930
Operating status
Operating
Headcount range
251–500 employees
Short description
Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer specializing in biological and biotechnological APIs (world leader in pancreatin and collagenase), branded products (Pankreatan, Thrombophob), and full-service CDMO services for global biopharma, research, and healthcare customers.
Ownership category
akta.pro rank

Nordmark Pharma industry classification

Industry
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)

Keywords

  • Biopharmaceutical manufacturing
  • Contract development manufacturing
  • Active pharmaceutical ingredients
  • Pancreatin collagenase production
  • Biological drug substance

Where Nordmark Pharma is headquartered

Location

Headquarters

HQ city
Uetersen
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

Nordmark Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Products: Sale of finished pharmaceutical products including Pankreatan (pancreatin) for pancreatic enzyme replacement therapy and Thrombophob (heparin-based cream) for sports injuries and superficial phlebitis. Products sold to patients via pharmacies and to healthcare professionals.
  2. Biochemicals: Sale of biochemical products including collagenases, neutral proteases, and clostripain for research and clinical applications. These are sold for in vitro use only, for research and laboratory purposes.
  3. Contract Manufacturing Services: Full service CDMO offering for biopharmaceutical companies - from development, analytical testing, clinical trials, regulatory support, and project management through to GMP manufacturing of drug substances and drug products for clinical supply (Phase I-III).
  4. Thyroid Extract: Production and sale of desiccated thyroid extract as a pharmaceutical product.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Nordmark Pharma product offering

Product offering

Core offering

Nordmark Pharma is a biopharmaceutical Full Service Provider specializing in the manufacture of active pharmaceutical ingredients and drug products of biological and biotechnological origin. The company offers the complete pharmaceutical value chain as a one-stop-shop—from development, analytical testing, clinical trial supply, regulatory support, and project management through to GMP manufacturing of drug substances and finished drug products. It also sells proprietary finished medications (Pankreatan, Thrombophob) and a comprehensive biochemical enzyme portfolio (Collagenase NB, Neutral Protease, Clostripain) for research and clinical applications.

Product overview

Nordmark Pharma operates as a biopharmaceutical Full Service Provider offering a vertically integrated portfolio combining proprietary pharmaceutical products and contract development and manufacturing (CDMO) services. The pharmaceutical arm includes patient medications Pankreatan (pancreatic enzyme replacement for exocrine insufficiency) and Thrombophob 60.000 (heparin-based topical for injuries and phlebitis), alongside active pharmaceutical ingredients Pancreatin, Collagenase, and Desiccated Thyroid Extract where Nordmark holds global market leadership positions. The biochemicals portfolio features the comprehensive Collagenase NB product line in multiple grades (Premium, Proved, Standard, Sterile, GMP, Gentle, Broad Range) plus Neutral Protease and Clostripain enzymes for research and clinical applications. Through subsidiaries Nordmark Biotech and BIBITEC, the company provides end-to-end CDMO services spanning drug substance manufacturing via microbial fermentation (up to 500L) and mammalian cell culture (up to 200L), through drug product formulation (orals, topicals, parenterals), all under cGMP conditions for clinical trial supply (Phase I-III) and commercial production—positioniting Nordmark as a one-stop-shop covering the complete pharmaceutical value chain from development through regulatory approval and market supply.

Differentiator

Problem solved

Functional benefit

Brands

  • Pankreatan: Pharmaceutical product for pancreatic exocrine insufficiency (PEI)
  • Thrombophob
  • BIBITEC
  • Nordmark Biochemicals
  • Nordmark Biotech

Companies that use Nordmark Pharma

Customer profile

Segments4 records

Ideal customer profiles3 records

Nordmark Pharma technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Nordmark Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BIBITECcoreStrategic or Co-development PartnerBIBITEC is a wholly-owned subsidiary of Nordmark conducting mammalian cell culture-based process development and protein production. Located in Bielefeld, Germany, BIBITEC handles upstream development of mammalian cell culture processes from lab scale (<1 L) to pilot scale (up to 200 L) for GMP clinical supply manufacturing.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Nordmark Pharma competitors and assessment

Company assessment

Direct peers

  • Celonic Group: German-headquartered CDMO offering mammalian and microbial GMP biomanufacturing plus process development for clinical and commercial supply. Highly comparable technology stack (CHO/microbial) and mid-market European CDMO positioning.
  • Siegfried Holding: Swiss CDMO offering API manufacturing including biologics and finished drug products to pharma clients. Comparable vertical integration from API to finished dosage form and European-headquartered mid-market CDMO profile.
  • Vibalogics: German-based biologics CDMO with BSL-2 viral and gene therapy capabilities using mammalian and microbial expression systems. Comparable full-service positioning and German regulatory footprint to Nordmark Biotech.
  • Rentschler Biopharma: German biopharmaceutical CDMO focused on mammalian cell-culture process development and GMP manufacturing for clinical supply. Closely comparable to Nordmark's BIBITEC unit in scale (pilot-to-Phase III mammalian CDMO) and customer profile (European biotechs).
  • Worthington Biochemical: US-based supplier of collagenase, protease, and other enzymes for cell isolation and bioprocessing applications. Directly comparable biochemical product portfolio to Nordmark Biochemicals' Collagenase NB and Neutral Protease lines.

Broad incumbents

  • Stada Arzneimittel: German specialty/generic pharmaceutical company selling finished drug products across Europe. Comparable as a German-headquartered branded specialty pharma selling into pharmacies and HCPs, though at significantly larger scale and broader portfolio than Nordmark.
  • Catalent Biologics: Global biologics CDMO offering cell-line development, process development, and GMP manufacturing for mammalian-based biotherapeutics. Comparable full-service value proposition but at commercial-scale bioreactor capacities.
  • Lonza Biologics: Global leader in mammalian and microbial biologics contract manufacturing across all clinical and commercial scales. Competes with Nordmark for European biopharma CDMO work but at vastly larger capacity (10,000L+ stainless and 2,000L+ single-use).
  • Boehringer Ingelheim BioXcellence: Larger German biopharmaceutical CDMO division of Boehringer Ingelheim offering mammalian and microbial contract manufacturing at commercial scale. Overlaps with Nordmark's CDMO offering but operates at materially larger bioreactor scale.

Regional players

  • SERVA Electrophoresis: German supplier of biochemicals, enzymes, and life-science research reagents serving European academic and biotech customers. Comparable as a German specialty biochemical products supplier, though broader product scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Nordmark Pharma social profiles

Digital presence

Nordmark Pharma compliance and trust

Trust signal

Compliance2 records

Nordmark Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nordmark Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Nordmark Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Nordmark Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nordmark Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordmark Pharma

What does Nordmark Pharma do?

Nordmark Pharma is a biopharmaceutical Full Service Provider specializing in the manufacture of active pharmaceutical ingredients and drug products of biological and biotechnological origin. The company offers the complete pharmaceutical value chain as a one-stop-shop—from development, analytical testing, clinical trial supply, regulatory support, and project management through to GMP manufacturing of drug substances and finished drug products. It also sells proprietary finished medications (Pankreatan, Thrombophob) and a comprehensive biochemical enzyme portfolio (Collagenase NB, Neutral Protease, Clostripain) for research and clinical applications.

Is Nordmark Pharma a public or private company?

Nordmark Pharma is a private company. It is currently operating.

When was Nordmark Pharma founded?

Nordmark Pharma was founded in 1930. It employs 251 to 500 people.

Where is Nordmark Pharma based?

Nordmark Pharma is headquartered in Uetersen, Germany, in the Europe region.

How does Nordmark Pharma make money?

Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are biochemicals, contract Manufacturing Services and thyroid Extract.

Who are Nordmark Pharma's main competitors?

Direct peers on record are Celonic Group, Siegfried Holding, Vibalogics, Rentschler Biopharma and Worthington Biochemical. Broad incumbents are Stada Arzneimittel, Catalent Biologics, Lonza Biologics and Boehringer Ingelheim BioXcellence. SERVA Electrophoresis is listed as a regional player.

Does Nordmark Pharma have an API?

No public API is recorded for Nordmark Pharma.

What industry is Nordmark Pharma in?

Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals